173 related articles for article (PubMed ID: 34741789)
1. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
Heesterman BL; van der Poel HG; Schoots IG; Mehra N; Aben KKH
BJU Int; 2022 Aug; 130(2):217-225. PubMed ID: 34741789
[TBL] [Abstract][Full Text] [Related]
2. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
Ali A; Hoyle A; Mistry H; Clarke NW
BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
[TBL] [Abstract][Full Text] [Related]
3. Impact of non-regional lymph node metastases accurately revealed on
Jiang Z; Fan J; Gan C; Dong X; Gao G; Wang Z; He D; Li L; Duan X; Wu K
EJNMMI Res; 2023 Jul; 13(1):64. PubMed ID: 37410264
[TBL] [Abstract][Full Text] [Related]
4. Regional location of lymph node metastases predicts survival in patients with
Wang ZP; Chen JR; Zhao JG; Zhu S; Zhang XM; Liang JY; He B; Ni YC; Sun GX; Shen PF; Zeng H
Asian J Androl; 2023; 25(4):462-467. PubMed ID: 36348577
[TBL] [Abstract][Full Text] [Related]
5. M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.
Park H; Dahlberg SE; Lydon CA; Araki T; Hatabu H; Rabin MS; Johnson BE; Nishino M
Oncologist; 2019 Aug; 24(8):e749-e754. PubMed ID: 30696724
[TBL] [Abstract][Full Text] [Related]
6. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of M descriptors of the 8th edition of TNM classification of lung cancer.
Dias M; Antunes A; Campainha S; Conde S; Barroso A
J Thorac Dis; 2017 Mar; 9(3):685-691. PubMed ID: 28449476
[TBL] [Abstract][Full Text] [Related]
8. Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma.
Shen L; Li W; Wang S; Xie G; Zeng Q; Chen C; Shi F; Zhang Y; Wu M; Shu W; Pan C; Xia Y; Wu P
Radiology; 2016 Sep; 280(3):805-14. PubMed ID: 27023116
[TBL] [Abstract][Full Text] [Related]
9. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ali A; Hoyle A; Haran ÁM; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Dearnaley D; Attard G; Gillessen S; Parmar MKB; Parker CC; Sydes MR; James ND; Clarke NW
JAMA Oncol; 2021 Apr; 7(4):555-563. PubMed ID: 33599706
[TBL] [Abstract][Full Text] [Related]
10. Influence of nonregional lymph node metastasis as a prognostic factor in metastatic prostate cancer patients.
Cho S; Kang SG; Tae BS; Cheon J
Korean J Urol; 2012 Oct; 53(10):673-9. PubMed ID: 23136626
[TBL] [Abstract][Full Text] [Related]
11. Surgery on Metastatic Foci is a Better Strategy for Stage IV Breast Cancer Patients with only Nonregional Lymph Node Metastasis.
Jiao Y; Guo X; Wu H; Lv Q
Adv Ther; 2023 Jul; 40(7):3247-3262. PubMed ID: 37270436
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry.
Metzenmacher M; Griesinger F; Hummel HD; Elender C; Schäfer H; de Wit M; Kaiser U; Kern J; Jänicke M; Spring L; Zacharias S; Kaiser-Osterhues A; Groth A; Hipper A; Zaun G; Dörfel S; Güldenzoph B; Müller L; Uhlig J; Thomas M; Sebastian M; Eberhardt WEE;
Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36180086
[TBL] [Abstract][Full Text] [Related]
13. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
[TBL] [Abstract][Full Text] [Related]
14. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.
Sakai K; Kuramoto J; Kojima A; Nishimura H; Kuwabara Y; Toda M; Kobayashi Y; Kikuchi S; Hirata Y; Mikami-Saito Y; Mikami S; Kyoyama H; Moriyama G; Gemma A; Uematsu K
Int J Clin Oncol; 2019 Dec; 24(12):1549-1557. PubMed ID: 31452019
[TBL] [Abstract][Full Text] [Related]
15. Effect of M1a and M1b category in metastatic colorectal cancer.
Kennecke H; Yu J; Gill S; Cheung WY; Blanke CD; Speers C; Woods R
Oncologist; 2014 Jul; 19(7):720-6. PubMed ID: 24899642
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.
Gravis G; Autret A; Guibert-Broudic M; Dubergé T; Zemmour C; Carrier P; Salem N; Badinand D; Cartier L; Gross E; Walz J; Pignot G; Brenot-Rossi I
Clin Genitourin Cancer; 2021 Aug; 19(4):346-353. PubMed ID: 33849812
[TBL] [Abstract][Full Text] [Related]
17. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
18. Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.
Lin M; Yang Q; You R; Zou X; Duan CY; Liu YP; Huang PY; Xie YL; Wang ZQ; Liu T; Chen SY; Hua YJ; Chen MY
Oral Oncol; 2021 Apr; 115():105200. PubMed ID: 33610003
[TBL] [Abstract][Full Text] [Related]
19. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
[TBL] [Abstract][Full Text] [Related]
20. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
